uBiome has appointed Joseph Jimenez to its board of directors to support the firm's new drug discovery and development efforts. Prior to uBiome, Jimenez served as CEO of Novartis, where he focused on leading global businesses while divesting non-core divisions. Jimenez has a track record of business leadership at several companies, including Clorox, ConAgra, and H.J Heiz. In addition to uBiome's board of directors, Jimenez also serves on the boards of Procter & Gamble and General Motors. In addition, he served on the board of directors at Colgate-Palmolive from 2009 to 2015, and at AstraZeneca from 2002 to 2017.
Oncimmune has appointed Marco Casarin as General Manager, Oncimmune USA. Casarin previously held a position at Thermo Fisher Scientific. In addition, Casarin has held senior commercial, marketing, and operating roles at Roche Diagnostics and Vela Diagnostics.
Steven Riedmuller is the new CEO for Maxygen, a service provider for clients in synthetic biology, metabolic engineering, gene therapy, immunotherapy, and gene editing. Riedmuller most recently served as senior director for field applications at Synthetic Genomics. Prior to that, he was VP of engineering and business development at Hudson Robotics.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.